Issue: October 2020

Read more

October 20, 2020
1 min read
Save

ELDERCARE-AF

Issue: October 2020
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Low-dose edoxaban (Savaysa, Daiichi Sankyo) vs. placebo for prevention of stroke and systemic embolism in patients aged at least 80 years with AF.